Significance of the study:
Given that: (1) 15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD; and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.
From Research findings to Therapeutic opportunity:
This study suggests, first the first time, Bacillus Calmette Guerin (BCG) vaccine-based therapy, with detailed mechanistic insights, for lowering cholesterol and triglyceride levels, and to treat Non-alcoholic fatty liver disease (NAFLD) . BCG vaccine has been found to be useful in treatment for tuberculosis, for more than 100 years, more recently in the treatment of autoimmune diabetes. However, the mechanism of action remains largely unknown.
BCG vaccine, by increasing the expression of its target gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol and total cholesterol levels; (2) attenuate lipid deposition in liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, BCG vaccine, either alone or in combination with other drugs,may be used to treat NAFLD.
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does BCG vaccine decrease the expression of HMGCR and prevent NAFLD?
# Research cooperation
For purchase and payment details, you may reach us at email@example.com
* Research cooperation
Web: http://genomediscovery.org or http://newbioideas.com
Citation: Boominathan, L., A vaccine for lowering cholesterol, and triglycerides levels: Repurposing tuberculosis BCG vaccine into a cholesterol-lowering vaccine that inhibits Non-alcoholic fatty liver disease (NAFLD): BCG vaccine promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD, via down regulation of its target gene, 30/July/2018, 12.18 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite, drop us a line at firstname.lastname@example.org